Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

NCT01217931 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Kidney Cancer

Interventions

DRUG: Pazopanib
DRUG: Bevacizumab
DRUG: Everolimus

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]